Indo US Bio Tech Ltd Stock Price Today (NSE: INDOUS)
Fundamental Score
Indo US Bio Tech Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Indo US Bio Tech Ltd share price today is ₹145.23, up +0.00% on NSE/BSE as of 17 February 2026. Indo US Bio Tech Ltd (INDOUS) is a Small-cap company in the Other Agricultural Products sector with a market capitalisation of ₹251.38 (Cr). The 52-week high for INDOUS share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 14.89x, INDOUS is currently trading below its industry average P/E of 21.07x. The company has a Return on Equity (ROE) of 23.03% and a debt-to-equity ratio of 0.32.
Indo US Bio Tech Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Indo US Bio Tech Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Indo US Bio Tech Share Price: A Conservative Value Investor's Perspective
Examining the Indo US Bio Tech share price of ₹125.949997 requires a cautious, value-oriented approach. A unique aspect of the "Other Agricultural Products" industry is its sensitivity to monsoon patterns and commodity price fluctuations. Consequently, consistent profitability is paramount. This analysis of Indo US Bio Tech Ltd, part of an 80-parameter fundamental audit verified by Sweta Mishra, focuses on capital safety and long-term value preservation.
The company's Price-to-Earnings (PE) ratio of 14.89 suggests a reasonable valuation compared to the broader market. However, a deeper dive into sector peers is essential. While
Kaveri Seed Company Limited enjoys a strong reputation for management quality and consistent execution, it remains to be seen if Indo US Bio Tech Ltd exhibits a comparable level of operational efficiency and strategic foresight. Comparing capital allocation decisions and long-term strategic vision are crucial steps in assessing the true intrinsic value.A key factor supporting Indo US Bio Tech Ltd's competitive position is its Return on Capital Employed (ROCE) of 21.15%. This robust ROCE indicates the company's ability to generate significant profits from its invested capital. A consistently high ROCE can contribute to the formation of an economic moat, allowing the company to reinvest profits at attractive rates, further compounding shareholder value. However, the sustainability of this ROCE over the long term needs careful monitoring, taking into account competitive pressures and evolving industry dynamics.
Further investigation should involve analyzing Indo US Bio Tech Ltd's debt levels, cash flow generation, and dividend policy. A strong balance sheet, positive free cash flow, and a history of responsible capital allocation are essential attributes for a value investor seeking long-term capital preservation. A thorough examination of these factors will help determine whether the current Indo US Bio Tech share price offers a sufficient margin of safety.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Indo US Bio Tech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of INDOUS across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (23.03%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (21.15%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (15.82%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 14.89 vs Industry: 21.07)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (39.15%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (21.17% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (35.88% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (44.98% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (12.44x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (70.17%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Profit Decline Concern (-20.87%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Negative Free Cash Flow (₹-3.86 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Indo US Bio Tech Ltd Financial Statements
Comprehensive financial data for Indo US Bio Tech Ltd including income statement, balance sheet and cash flow
About INDOUS (Indo US Bio Tech Ltd)
Indo US Bio Tech Ltd (INDOUS) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Other Agricultural Products sector with a current market capitalisation of ₹251.38 (Cr). Indo US Bio Tech Ltd has delivered a Return on Equity (ROE) of 23.03% and a ROCE of 21.15%. The debt-to-equity ratio stands at 0.32, reflecting the company's capital structure. Investors tracking INDOUS share price can monitor key metrics including P/E ratio, promoter holding of 70.17%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
INDOUS Share Price: Frequently Asked Questions
What is the current share price of Indo US Bio Tech Ltd (INDOUS)?
As of 17 Feb 2026, 10:11 am IST, Indo US Bio Tech Ltd share price is ₹145.23. The INDOUS stock has a market capitalisation of ₹251.38 (Cr) on NSE/BSE.
Is INDOUS share price Overvalued or Undervalued?
INDOUS share price is currently trading at a P/E ratio of 14.89x, compared to the industry average of 21.07x. Based on this relative valuation, the Indo US Bio Tech Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of INDOUS share price?
The 52-week high of INDOUS share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Indo US Bio Tech Ltd share price?
Key factors influencing INDOUS share price include quarterly earnings growth (Sales Growth: 39.15%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Indo US Bio Tech Ltd a good stock for long-term investment?
Indo US Bio Tech Ltd shows a 5-year Profit Growth of 44.98% and an ROE of 23.03%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.32 before investing in INDOUS shares.
How does Indo US Bio Tech Ltd compare with its industry peers?
Indo US Bio Tech Ltd competes with major peers in the Other Agricultural Products. Investors should compare INDOUS share price P/E of 14.89x and ROE of 23.03% against the industry averages to determine competitive standing.
What is the P/E ratio of INDOUS and what does it mean?
INDOUS share price has a P/E ratio of 14.89x compared to the industry average of 21.07x. Investors pay ₹15 for every ₹1 of annual earnings.
How is INDOUS performing according to Bull Run's analysis?
INDOUS has a Bull Run fundamental score of 65/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does INDOUS belong to?
INDOUS operates in the Other Agricultural Products industry. This classification helps understand the competitive landscape and sector-specific trends affecting Indo US Bio Tech Ltd share price.
What is Return on Equity (ROE) and why is it important for INDOUS?
INDOUS has an ROE of 23.03%, which indicates excellent management efficiency. ROE measures how efficiently Indo US Bio Tech Ltd generates profits from shareholders capital.
How is INDOUS debt-to-equity ratio and what does it indicate?
INDOUS has a debt-to-equity ratio of 0.32, which indicates moderate leverage that should be monitored.
What is INDOUS dividend yield and is it a good dividend stock?
INDOUS offers a dividend yield of 0.20%, meaning you receive ₹0.20 annual dividend for every ₹100 invested in Indo US Bio Tech Ltd shares.
How has INDOUS share price grown over the past 5 years?
INDOUS has achieved 5-year growth rates of: Sales Growth 21.17%, Profit Growth 44.98%, and EPS Growth 35.88%.
What is the promoter holding in INDOUS and why does it matter?
Promoters hold 70.17% of INDOUS shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Indo US Bio Tech Ltd.
What is INDOUS market capitalisation category?
INDOUS has a market capitalisation of ₹251 crores, placing it in the Small-cap category.
How volatile is INDOUS stock?
INDOUS has a beta of N/A. A beta > 1 suggests the Indo US Bio Tech Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is INDOUS operating profit margin trend?
INDOUS has a 5-year average Operating Profit Margin (OPM) of 15.82%, indicating the company's operational efficiency.
How is INDOUS quarterly performance?
Recent quarterly performance shows Indo US Bio Tech Ltd YoY Sales Growth of 39.15% and YoY Profit Growth of -20.87%.
What is the institutional holding pattern in INDOUS?
INDOUS has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Indo US Bio Tech Ltd stock.